Abstract
Although the cause of KD remains unknown, understanding of its pathogenesis has increased. An overt immune reaction triggered by unknown infectious agents may cause systemic vasculitis. The mediators of this reaction are mainly inflammatory cytokines such as TNF-α, IL-1β, and IFN-γ. Several genetic factors differentially affect susceptibility to KD in various ethnic groups. However, the mechanisms of overt immune reaction during acute KD and the cytokines/biomarkers that are best able to predict KD severity are not well understood. Knowledge of the systems biology of complex cytokine networks is essential for the development of new diagnostic and therapeutic strategies to prevent CAL formation in KD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644–9.e1. http://dx.doi.org/10.1016/j.jpeds.2010.10.012 PMID:21129756.
Leung DY, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med. 1986;164(6):1958–72. http://dx.doi.org/10.1084/jem.164.6.1958 PMID:3491174.
Miethke T, Duschek K, Wahl C, Heeg K, Wagner H. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol. 1993;23(7):1494–500. http://dx.doi.org/10.1002/eji.1830230715 PMID:8325325.
Ueno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T, et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol. 1989;76(3):337–42. PMID:2473858.
Terai M, Jibiki T, Harada A, Terashima Y, Yasukawa K, Tateno S, et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment. J Leukoc Biol. 1999;65(5):566–72. PMID:10331483.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, et al. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine. 2012;60(3):681–5. http://dx.doi.org/10.1016/j.cyto.2012.08.006 PMID:22944461.
Angelone DF, Wessels MR, Coughlin M, Suter EE, Valentini P, Kalish LA, et al. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatr Res. 2006;60(2):205–9. http://dx.doi.org/10.1203/01.pdr.0000228319.10481.ea PMID:16864705.
Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol. 2009;183(11):7150–60. http://dx.doi.org/10.4049/jimmunol.0901481 PMID:19917677.
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.592865 PMID:16735679.
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40. http://dx.doi.org/10.1016/j.jpeds.2006.03.050 PMID:16887442.
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7. http://dx.doi.org/10.1007/s00431-006-0223-z PMID:16896641.
Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, Pediatric Heart Network Investigators, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–5.e3. http://dx.doi.org/10.1016/j.jpeds.2010.10.031 PMID:21168857.
Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153(1):117–21. http://dx.doi.org/10.1016/j.jpeds.2007.12.021 PMID:18571548.
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol. 2008;122(5):1008–13.e8. http://dx.doi.org/10.1016/j.jaci.2008.09.011 PMID:18930517.
Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW, Sundel RP, et al. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007;8(12):R261. http://dx.doi.org/10.1186/gb-2007-8-12-r261 PMID:18067656.
Matsuda A, Morita H, Unno H, Saito H, Matsumoto K, Hirao Y, et al. Anti-inflammatory effects of high-dose IgG on TNF-α-activated human coronary artery endothelial cells. Eur J Immunol. 2012;42(8):2121–31. http://dx.doi.org/10.1002/eji.201242398 PMID:22585560.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013;65(3):805–14. http://dx.doi.org/10.1002/art.37815 PMID:23440694.
Abe J. Cytokines in Kawasaki disease [Japanese]. Nippon Rinsho. 2014;72:2014–19.
Kentsis A, Shulman A, Ahmed S, Brennan E, Monuteaux MC, Lee YH, et al. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med. 2013;5(2):210–20. http://dx.doi.org/10.1002/emmm.201201494 PMID:23281308.
Ogata S, Shimizu C, Franco A, Touma R, Kanegaye JT, Choudhury BP, et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One. 2013;8(12), e81448. http://dx.doi.org/10.1371/journal.pone.0081448 PMID:24324693.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan
About this chapter
Cite this chapter
Abe, J. (2017). Immunological Abnormalities and Use of Biomarkers and Cytokines to Predict the Severity of Kawasaki Disease. In: Saji, B., Newburger, J., Burns, J., Takahashi, M. (eds) Kawasaki Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56039-5_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-56039-5_5
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56037-1
Online ISBN: 978-4-431-56039-5
eBook Packages: MedicineMedicine (R0)